Cachexia and obesity: Two sides of one coin?

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 6, Issue 4, 2003, Pages 395-399

  Inui, Akio ^a   Meguid, Michael M ^b  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Anorexigenic signal; Cachexia; Cytokine; Leptin; Obesity; Orexigenic signal

Indexed keywords

AGOUTI RELATED PROTEIN; ALPHA INTERMEDIN; ANOREXIGENIC AGENT; APPETITE STIMULANT; CILIARY NEUROTROPHIC FACTOR; CORTICOTROPIN RELEASING FACTOR; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; JANUS KINASE; LEPTIN; LEPTIN RECEPTOR; LEUKEMIA INHIBITORY FACTOR; MELANOCORTIN; MELANOCORTIN 4 RECEPTOR; NEUROPEPTIDE Y; PROOPIOMELANOCORTIN; STAT PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ANOREXIA; APPETITE; BODY WEIGHT; CACHEXIA; CANCER PATIENT; CYTOKINE PRODUCTION; ENERGY METABOLISM; FEEDING BEHAVIOR; GENE EXPRESSION; HUMAN; HYPERPHAGIA; HYPOTHALAMUS; MUSCLE METABOLISM; OBESITY; PROTEIN DEGRADATION; REVIEW; STARVATION;

ANOREXIA; BODY WEIGHT; CACHEXIA; ENERGY METABOLISM; HOMEOSTASIS; HUMANS; LEPTIN; OBESITY;

EID: 0345443373     PISSN: 13631950     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075197-200307000-00007     Document Type: Review

References (42)

1. Beutler B, Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med 1987; 316:379-385.
2. Nelson KA, Walsh D, Sheehan FA. The cancer anorexia-cachexia syndrome. J Clin Oncol 1994; 12:213-225.
3. Higginson I, Bruera E. Pratical concepts for clinicians. In: Bruera E, Higginson I, editors. Cachexia-anorexia in cancer patients. Oxford: Oxford University Press; 1996. pp. 185-189.
4. Bruera E. Anorexia, cachexia, and nutrition. BMJ 1997; 315:1219-1222.
5. Kotler DP. Cachexia. Ann Intern Med 2000; 133:622-634.
6. Inui A. Cancer anorexia-cachexia syndrome: Current issues in research and management. Ca Cancer J Clin 2002; 52:72-91. This presents an overview of research and pharmacological manipulation of appetite and other central and peripheral mechanisms involved in cachectic processes.
7. Inui A. Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer Res 1999; 59:4493-4501.
8. Tisdale MJ. Biology of cachexia. J Natl Cancer Inst 1997; 89:1763-1773.
9. Tisdale MJ. Cancer anorexia and cachexia. Nutrition 2001; 17:438-442.
10. Moldawer LL, Copeland EM 3rd. Proinflammatory cytokines, nutritional support, and the cachexia syndrome: Interactions and therapeutic options. Cancer 1997; 79:1828-1839.
11. Plata-Salaman CR. Central nervous system mechanisms contributing to the cachexia-anorexia syndrome. Nutrition 2000; 16:1009-1012.
12. Meguid MM, Fetissov SO, Varma M, et al. Hypothalamic dopamine and serotonin in the regulation of food intake. Nutrition 2000; 16:843-857.
13. B in the normal rat hypothalamus. Neurosci Lett 2002; 328:155-159.
14. Sonti G, Ilyin SE, Plata-Salaman CR. Anorexia induced by cytokine interactions at pathophysiological concentrations. Am J Physiol Regul Integr Comp Physiol 1996; 270:1394-1402.
15. Inui A. Cytokines and sickness behavior: Implications from knockout animal models. Trends Immunol 2001; 22:469-473.
16. Dantzer R. Cytokine-induced sickness behavior: where do we stand? Brain Behav Immun 2001; 15:7-24.
17. Tohgo A, Kumazawa E, Akahane K, et al. Anticancer drugs that induce cancer-associated cachectic syndromes. Expert Rev Anticancer Ther 2002; 2:121-129.
18. Sternberg EM. Neural-immune interactions in health and disease. J Clin Invest 1997; 100:2641-2647.
19. Opara EI, Laviano A, Meguid MM, Yang ZJ. Correlation between food intake and CSF IL-1 alpha in anorectic tumor bearing rats. Neuroreport 1995; 6:750-752.
20. Debonis D, Meguid MM, Laviano A, et al. Temporal changes in meal number and meal size relationship in response to rHu IL-1 alpha. Neuroreport 1995; 6:1752-1756.
21. Luheshi GN, Gardner JD, Rushforth DA, et al. Leptin actions on food intake and body temperature are mediated by IL-1. Proc Natl Acad Sci U S A 1999; 96:7047-7052.
22. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395:763-770.
23. Schwartz MW, Woods SC, Porte D Jr, et al. Central nervous system control of food intake. Nature 2000; 404:661-671.
24. Inui A. Transgenic approach to the study of body weight regulation. Pharmacol Rev 2000; 52:35-61.
25. Schwartz MW, Seeley RJ. Neuroendocrine responses to starvation and weight loss. N Engl J Med 1997; 336:1802-1811.
26. Chance WT, Balasubramaniam A, Dayal R, et al. Hypothalamic concentration and release of neuropeptide Y into microdialysates is reduced in anorectic tumor-bearing rats. Life Sci 1994; 54:1869-1874.
27. McCarthy HD, McKibbin PE, Perkins AV, et al. Alterations in hypothalamic NPY and CRF in anorexic tumor-bearing rats. Am J Physiol Endocrinol Metab 1993; 264:638-643.
28. Makarenko I, Meguid MM, Gatto L, et al. Decreased NPY innervation of the hypothalamic nuclei in rats with cancer anorexia. Brain Res 2002; 961:100-108.
29. Chance WT, Balasubramaniam A, Sheriff S. Neuropeptide Y and cancer anorexia. Curr Med Chem - Central Nervous System Agents 2003; 3 (in press).
30. Marks DL, Ling N, Cone RD. Role of the central melanocortin system in cachexia. Cancer Res 2001; 61:1432-1438.
31. Wisse BE, Frayo RS, Schwartz MW, Cummings DE. Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology 2001; 142:3292-3301.
32. Rosenbaum M, Leibel RL, Hirsch J. Obesity. N Engl J Med 1997; 337:395-407.
33. Bray GA, Tartaglia LA. Medicinal strategies in the treatment of obesity. Nature 2000; 404:672-677.
34. Laviano A, Meguid MM, Yang ZJ, et al. Cracking the riddle of cancer anorexia. Nutrition 1996; 12:706-710.
35. Mantovani G, Maccio A, Massa E, Madeddu C. Managing cancer-related anorexia/cachexia. Drugs 2001; 61:499-514.
36. MacDonald N. Cachexia-anorexia workshop summary and conclusions. Nutrition 2000; 16:1019-1020.
37. Inui A. Ghrelin: an orexigenic and somatotrophic signal from the stomach. Nat Rev Neurosci 2001; 2:551-560.
38. Lambert PD, Anderson KD, Sleeman MW, et al. Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc Natl Acad Sci U S A 2001; 98:4652-4657.
39. Korner J, Aronne LJ. The emerging science of body weight regulation and its impact on obesity treatment. J Clin Invest 2003; 111:565-570.
40. Crowley VE, Yeo GS, O'Rahilly S. Obesity therapy: altering the energy intake-and-expenditure balance sheet. Nat Rev Drug Discov 2002; 1:276-286. This informative paper describes obesity therapy by altering the balance between energy intake and expenditure.
41. Nandi J, Meguid MM, Inui A, et al. Central mechanisms involved with catabolism. Curr Opin Clin Nutr Metab Care 2002; 5:407-418. This is a review of central mechanisms involved with catabolism, describing a variety of neurohormonal, monoaminergic and peptidergic mediators.
42. Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer 2002; 2:862-871. This is a review on catabolic factors acting to destroy host tissues such as muscle and fat.